A study of 250 stroke patients sounds like strong evidence. It is the largest human dataset for palmitoylethanolamide in any neurological condition, every measure improved, and the results are statistically significant.
It also had no control group, and the people in it were in active neurorehabilitation, which is the single setting where large spontaneous improvement is guaranteed regardless of what anyone swallows.
The paper is unusually honest about this. Its own authors describe the work as observational and call for controlled trials. That candour is worth carrying into how the numbers get read.
Key Takeaways
- A cohort of 250 stroke patients undergoing inpatient or outpatient neurorehabilitation was treated for 60 days with a co-ultramicronized PEA and luteolin preparation [1].
- Patients were assessed at baseline and after 30 days on neurological status, cognitive impairment, spasticity, pain and independence in daily living, and all indices showed statistically significant gains at study end [1].
- There was no control group. The authors describe the study as observational and state that further controlled trials are warranted [1].
- The same paper includes a rat middle cerebral artery occlusion arm showing reduced edema, reduced infarct volume and improved neurobehavioral function [1]. That is animal data and should not be blended with the human arm.
- The paper opens by noting that anti-inflammatory and neuroprotective compounds identified in animal stroke models have repeatedly failed to translate into positive human clinical trials [1], which is the correct frame for reading it.
The Problem This Study Was Trying to Solve
Acute ischemic stroke is the most frequent cause of permanent disability in adults worldwide, resulting from a transient or permanent reduction in regional cerebral blood flow, and involving oxidative stress and inflammation [1].
The paper’s own opening is the most important sentence in it. Despite the success of experimental animal models of stroke in identifying anti-inflammatory and neuroprotective compounds, translation of these putative neuroprotectants to human clinical trials has failed to produce a positive outcome [1].
Stroke neuroprotection is a graveyard. Compound after compound has looked excellent in rodents and done nothing in people. Any new candidate arrives carrying that history, and any reader should apply it here too.
The rationale for PEA is the standard one. Tissue injury and stress activate endogenous mechanisms that restore homeostatic balance and limit further damage by upregulating lipid signalling molecules including PEA, which exerts neuroprotection and reduces inflammatory secondary events associated with brain ischemia reperfusion injury [1]. Reviews frame PEA broadly as a way of keeping neuroinflammation within physiological boundaries [2].
The Two Arms, Kept Separate
The study had two distinct parts and they need to stay separate, because merging them is how this paper gets overstated.
Research note: In ten patients with a first acute ischemic stroke and eight controls, blood PEA was not significantly different from controls but correlated with NIHSS neurological severity scores [6].
The first arm was in rats. Animals subjected to middle cerebral artery occlusion and treated with the co-ultramicronized PEA and luteolin composite after ischemia showed reduced edema and brain infarct volume, improved neurobehavioral function, and reduced expression of pro-inflammatory and astrocyte markers [1]. The composite itself is PEA and the antioxidant flavonoid luteolin at 10 to 1 by mass, referred to as co-ultraPEALut [1].
The second arm was in people. A cohort of 250 stroke patients undergoing neurorehabilitation on either an inpatient or outpatient basis was treated for 60 days with a pharmaceutical preparation of the same composite [1]. At baseline and after 30 days of treatment, all patients underwent a battery of evaluations covering neurological status, impairment of cognitive abilities, degree of spasticity, pain, and independence in daily living activities [1]. All indices showed statistically significant gains at study end [1].
The rat arm shows what the compound does to infarct volume in a controlled experiment. The human arm shows what happened to 250 people who took it while also receiving rehabilitation. Those are answers to different questions.
Why No Control Group Is Decisive Here
Every patient in the human arm received the treatment. There was no comparison group, and the authors label the work observational themselves [1].
In most conditions, an uncontrolled before-and-after study is weak because of placebo response and regression to the mean. In stroke rehabilitation it is weaker still, for a reason specific to the setting: substantial recovery happens on its own. Neurological function, spasticity, cognition and independence all tend to improve in the months after a stroke, and neurorehabilitation is designed to accelerate exactly those gains. Measuring 250 patients at baseline and again 30 days into a rehabilitation programme will show improvement in essentially any cohort.
The authors are alert to this. Their claim is carefully worded: despite its observational nature, this represents the first description of the composite being administered to human stroke patients, with clinical improvement not otherwise expected from spontaneous recovery, and further controlled trials are warranted to confirm the utility of the compound in improving clinical outcome [1].
That phrase, not otherwise expected from spontaneous recovery, is the study’s central claim and also the one thing its design cannot demonstrate. Without a control arm receiving rehabilitation alone, there is no measurement of what would otherwise have been expected. It is a clinical judgement by experienced investigators, which is worth something, and it is not data.
What Would Settle It
The trial that would answer this question is straightforward to describe: stroke patients entering neurorehabilitation randomized to the composite or to placebo, with the same battery of outcome measures, assessors blinded to allocation. Reviews covering PEA across neurodegenerative and neurological conditions consistently arrive at the same place, describing a field whose evidence runs from rodents toward humans without having arrived [3].
One smaller trial has since added a comparison group. In 60 patients with acute ischemic stroke undergoing thrombolysis, PEALut (PEA 700 mg + luteolin 70 mg) was started within 72 hours of onset on top of alteplase and standard care, while the comparison group received thrombolysis alone, so it was open-label and not placebo-controlled. Independence in daily living (Barthel Index) and disability (modified Rankin Scale) improved more with PEALut, but the cognitive benefit was not tested against the control group because too few control patients could complete the tests. Epitech Group, which makes the product, supplied it [5].
Elsewhere in the neurological literature, the compound has now had a properly controlled test. A Phase 2 randomized, double-blind, placebo-controlled trial in frontotemporal dementia found less decline on its primary outcome with PEA plus luteolin, which this site covers in a separate article. That is what a controlled result looks like, and its numbers are far more modest than the sweeping improvements reported in the uncontrolled stroke cohort. The contrast is instructive.
Preclinical work continues to provide the mechanistic rationale, including rodent evidence that PEA controls reactive gliosis and exerts neuroprotective functions through PPAR-alpha [4]. Mechanism explains why an idea is worth testing. It does not substitute for the test.
If Someone in Your Family Has Had a Stroke
Stroke recovery is one of the areas where families are most exposed to overstated supplement claims, because the stakes are high, the recovery window feels urgent, and conventional options after the acute phase are mostly rehabilitation and secondary prevention.
What the evidence supports saying is that one large uncontrolled cohort reported significant gains across neurological, cognitive, spasticity, pain and independence measures over 60 days of a PEA and luteolin preparation added to rehabilitation [1], and that the one controlled comparison found so far is a separate 60-patient trial that was open-label, with no placebo and a comparison group that received thrombolysis alone [5].
What it does not support is treating the compound as a recovery accelerator with demonstrated benefit, or as any reason to modify secondary prevention. Anticoagulation, blood pressure control and statin therapy after a stroke rest on large randomized evidence. A supplement with one uncontrolled cohort and one small open-label trial behind it does not belong in the same conversation [1][5], and any addition to a post-stroke regimen belongs with the treating neurologist.
Frequently Asked Questions
Does PEA help stroke recovery?
An observational study of 250 stroke patients in neurorehabilitation reported statistically significant improvement across all measured indices over 60 days of a PEA and luteolin preparation [1]. Without a control group, that improvement cannot be separated from rehabilitation and spontaneous recovery.
How long did patients take it?
Sixty days, with assessments at baseline and after 30 days of treatment [1].
Was it PEA alone?
No. It was a co-ultramicronized composite of PEA and the flavonoid luteolin at a 10 to 1 mass ratio [1].
What about the animal results in the same paper?
Rats subjected to middle cerebral artery occlusion showed reduced edema, reduced infarct volume, better neurobehavioral function and lower inflammatory marker expression [1]. That is a controlled animal experiment and should not be merged with the human cohort.
Why be sceptical when the results were significant?
Because significance measures whether a change occurred, not what caused it. In an uncontrolled cohort in active rehabilitation, improvement is expected. The paper itself notes that anti-inflammatory compounds successful in animal stroke models have repeatedly failed in human trials [1].
References
- Caltagirone C, Cisari C, Schievano C, et al. Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man. Transl Stroke Res (2016). PMID 26706245
- Petrosino S, Schiano Moriello A. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries. Int J Mol Sci (2020). PMID 33333772
- Beggiato S, Tomasini MC, Ferraro L, et al. Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. Biomolecules (2022). PMID 35625595
- Scuderi C, Stecca C, Valenza M, et al. Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer disease. Cell Death Dis (2014). PMID 25210802
- Bonzanino M et al. PEALut in the Dietary Management of Patients with Acute Ischemic Stroke: A Prospective Randomized Controlled Clinical Trial. Journal of clinical medicine (2024). PMID 38256644
- Naccarato M et al. Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids in health and disease (2010). PMID 20470384
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.